Alliance Pharma PLC Hardman Res.: Transformed International Business

TIDMAPH

Alliance Pharma PLC

25 May 2017

Hardman Res.: Transformed International Business

Transformed International Business - Alliance Pharma's buy-and-build strategy to evolve into a profitable, cash generative, specialty pharma business is clearly bearing fruit. Acquisition of the dermatology and woundcare products from Sinclair Pharma was transformational, doubling the size of the company and providing a more internationally-oriented business. The enlarged group is also a more attractive and credible partner for in-licensing and M&A opportunities. 2017 looks set to be an exciting year for the group: not only is there solid underlying growth potential in the re-focused group, but also regulatory approval of Diclectin offers further significant growth potential.

Please click here for the full report:

http://www.hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/25.05.17-a-transformational-year-driving-growth.pdf

 
 To contact us:         Contacts: 
  Hardman & Co           Dr Martin Hall 
  35 New Broad Street    [e-mail] 
  London                 Dr Dorothea Hill 
  EC2M 1NH               [e-mail] 
                         Dr Gregoire Pave 
                         [e-mail] 
                         Telephone: [phone] 
                         Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGMGZKNDZGNZM

(END) Dow Jones Newswires

May 25, 2017 02:15 ET (06:15 GMT)